Credit Suisse’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-111,102
| Closed | -$2.11M | – | 4361 |
|
|
2019
Q1 | $2.11M | Buy |
+111,102
| New | +$1.8M | ﹤0.01% | 2335 |
|
|
2017
Q1 | – | Sell |
-12,200
| Closed | -$60K | – | 4309 |
|
|
2016
Q4 | $60K | Sell |
12,200
-387
| -3% | -$1.98K | ﹤0.01% | 4004 |
|
|
2016
Q3 | $62K | Sell |
12,587
-2,298
| -15% | -$11.8K | ﹤0.01% | 3994 |
|
|
2016
Q2 | $76K | Sell |
14,885
-8,398
| -36% | -$45.2K | ﹤0.01% | 4100 |
|
|
2016
Q1 | $133K | Sell |
23,283
-9,215
| -28% | -$64.4K | ﹤0.01% | 3778 |
|
|
2015
Q4 | $338K | Buy |
32,498
+6,311
| +24% | +$85.7K | ﹤0.01% | 3627 |
|
|
2015
Q3 | $483K | Sell |
26,187
-19,901
| -43% | -$384K | ﹤0.01% | 3420 |
|
|
2015
Q2 | $897K | Buy |
46,088
+16,555
| +56% | +$293K | ﹤0.01% | 3282 |
|
|
2015
Q1 | $520K | Buy |
29,533
+10,128
| +52% | +$170K | ﹤0.01% | 3522 |
|
|
2014
Q4 | $310K | Sell |
19,405
-353
| -2% | -$4.73K | ﹤0.01% | 4037 |
|
|
2014
Q3 | $249K | Buy |
19,758
+2,245
| +13% | +$32K | ﹤0.01% | 4028 |
|
|
2014
Q2 | $274K | Sell |
17,513
-41,934
| -71% | -$617K | ﹤0.01% | 4170 |
|
|
2014
Q1 | $781K | Buy |
59,447
+15,905
| +37% | +$249K | ﹤0.01% | 3344 |
|
|
2013
Q4 | $700K | Sell |
43,542
-11,530
| -21% | -$184K | ﹤0.01% | 3547 |
|
|
2013
Q3 | $917K | Buy |
55,072
+8,637
| +19% | +$128K | ﹤0.01% | 3037 |
|
|
2013
Q2 | $468K | Buy |
+46,435
| New | +$488K | ﹤0.01% | 3344 |
|
Other funds holding OSIR
Credit Suisse's OSIR Position: Q2 2019 in Review
Credit Suisse sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q2 2019, closing a stake of 111,102 shares — an estimated $2.11M sold.
Credit Suisse first reported a position in OSIR in Q2 2013 and held it in 16 quarters. The position peaked at $2.11M in Q1 2019. 1 fund tracked by Wall St. Rank holds OSIR as of Q2 2019.
- Credit Suisse reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
- Credit Suisse sold 111,102 Osiris Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $2.11M.
- Credit Suisse first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and held it in 16 quarters.
- Credit Suisse's Osiris Therapeutics, Inc. Common Stock position peaked at $2.11M in Q1 2019.
- 1 fund tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q2 2019.
Based on Credit Suisse's 13F filing for Q2 2019, filed 14 Aug 2019.